SCHEMBL3002912

SCHEMBL3002912

Cc1cc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DNM1L O00429 7/20 0.36
GBA1 P04062 1/20 0.34
LPAR2 Q9HBW0 4/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
AR P10275 1/20 0.34
LPAR1 Q92633 3/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009827 0.93 LMNA (0.36) LMNAL3MBTL1DNM1LGBA1LPAR2
SCHEMBL3012839 0.92 DNM1L (0.35) L3MBTL1DNM1LGBA1LPAR2MAPT
SCHEMBL3015958 0.91 KMT2A (0.38) LMNADNM1LGBA1MAPTALDH1A1
SCHEMBL3007833 0.90 LMNA (0.37) LMNAL3MBTL1DNM1LGBA1LPAR2
SCHEMBL3017920 0.90 VCAM1 (0.39) LMNADNM1LMAPTALDH1A1SMN1; SMN2
SCHEMBL3015515 0.89 GBA1 (0.42) DNM1LGBA1MAPTALDH1A1CYP1A2
SCHEMBL3015893 0.89 DNM1L (0.36) DNM1LGBA1MAPTALDH1A1CYP1A2
SCHEMBL3008159 0.88 RAB9A (0.39) DNM1LGBA1MAPTPOLBSMN1; SMN2
SCHEMBL3016660 0.88 GBA1 (0.38) LMNAL3MBTL1DNM1LGBA1MAPT
SCHEMBL3017996 0.87 LMNA (0.35) LMNAL3MBTL1DNM1LGBA1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885L3MBTL1 1847/4885DNM1L 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.